Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-25

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)

NCT05312918

HIV Infections

UNKNOWN

Investigating the Optimal Management of Dolutegravir Resistance

NCT06762054

HIV-1-infection

RECRUITING

HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen

NCT06285110

Hiv

COMPLETED

Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa

NCT04066036

HIV-1-infection

COMPLETED

The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH

NCT06044792

Hiv AIDS CD4 Deficiency +3 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research study consists of a single visit, in which you will be taken an additional vial of blood to analyze the presence or absence of mutations in your virus to HIV drugs. In addition, other HIV infection routine information will be recorded:

* Demographic data
* HIV infection history data
* Virological failure information
* Laboratory parameters Resistance tests techniques: Genotyping resistance test will be performed from plasma samples in those patients with viral load over 200 copies/ml, using ultracentrifugation if needed (Inzaule, Seth C et al. J Antimicrob Chemother, 2018). Briefly, RNA will be extracted and HIV-1 pol gene will be amplified, followed by a nested-PCR. Amplification products will be purified, quantified and finally diluted and prepared for sequencing following Illumina DNA Sample Preparation Kit protocol (Illumina, San Diego, CA). Samples will finally be pooled and sequenced in a MiSeq System (Illumina). MiSeq sequences will be downloaded from Basespace (Illumina) and analysed using PASeq (IrsiCaixa,Barcelona,ES), v1.4.18 (https://www.paseq.org). The questionnaire about clinical and demographic characteristics will be performed during the study visit

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV HIV Antiretroviral Therapy (ART) Adherence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-1 infected men or women >18 years controlled in the day care center of Chokwé Hospital

Not applicable- observational study

Intervention Type OTHER

Not applicable- observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Not applicable- observational study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients able to understand and sign the informed consent form.
* Documented HIV-1 infection.
* Under the first line TLD for at least 6 months.
* At least 3 months follow-up with CV \&amp;gt;200c/ml.

Exclusion Criteria

* Patients \&amp;lt;18 years of age.
* Under the first line regime other than TLD.
* Patients with active neoplastic processes.
* Patients with active opportunistic diseases.
* Patients unable to give informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No